Oncology

1. In patients with resected stage III mismatch repair-deficient colon cancer, adjuvant atezolizumab plus standard chemotherapy improved disease-free survival compared...

1. Statin use did not increase the risk of developing breast cancer among postmenopausal women. Evidence Rating Level: 2 (Good)...

Roche and NVIDIA deploy the pharmaceutical industry's largest AI factory A major leap in computational drug development has emerged with...

1. The combination of talazoparib and enzalutamide demonstrated a statistically significant improvement in radiographic progression-free survival for metastatic hormone-sensitive prostate...

Pfizer’s Talzenna combo significantly delays progression in frontline prostate cancer Topline results from the Phase 3 TALAPRO-3 study indicate that...

1. The mesenteric approach to pancreatoduodenectomy did not improve overall survival compared to the conventional Kocher-first approach in patients with...

1. Sitagliptin demonstrated the most prominent malignancy-related safety signal among the dipeptidyl peptidase-4 inhibitors studied. Evidence Rating Level: 2 (Good) ...

1.  In this randomized controlled trial, administering pegfilgrastim 72 hours after chemotherapy reduced bone pain compared with 24- or 48-hour...

1. Pyrotinib combined with trastuzumab and docetaxel prolonged progression-free survival compared to placebo combined with trastuzumab and docetaxel in patients...

1. Neoadjuvant capecitabine-oxaliplatin chemotherapy did not improve three-year disease-free survival compared to upfront surgery in locally advanced colon cancer. 2....